SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suraksha Diagnostic informs about outcome of board meeting

10 Nov 2025 Evaluate

With reference to letter dated 03 November 2025, Suraksha Diagnostic has informed that the Board of Directors of the Company, at its meeting held today, on Monday, 10 November 2025, has considered and approved the unaudited (standalone and consolidated) financial results of the Company for the quarter and six months ended 30 September 2025 along with Limited Review Report thereon, issued by the Statutory Auditors of the Company, enclosed as Annexure-1. The meeting of the Board of Directors commenced at 2.30 pm (IST) and concluded at 4.15 pm (IST).

The above information is a part of company’s filings submitted to BSE.

Suraksha Diagnostic Share Price

276.35 -0.45 (-0.16%)
13-Apr-2026 16:59 View Price Chart
Peers

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×